...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of neurology >Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study.
【24h】

Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study.

机译：急性中风患者服用尿酸后基质金属蛋白酶9亚型的变化过程：概念验证研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Oxidative stress as well as expression and activity of matrix metalloproteinase 9 (MMP-9) are rapidly enhanced after cerebral ischemia. The magnitude of these effects is related to stroke outcome. In human stroke, the extent of oxidative stress correlates well with increased MMP-9 expression. The aim of this study was to evaluate whether treatment with the antioxidant molecule uric acid (UA) decreased the levels of MMP-9 in stroke patients treated with rtPA. The patients were part of a pilot, double-blind, randomized, vehicle-controlled study of patients with acute stroke treated with rtPA (< 3 h) and randomized to receive an intravenous infusion of UA (n = 16) or vehicle (n = 8). Total matrix metalloproteinase (tMMP)-9 and active (aMMP-9) levels were measured in serum at baseline (< 3 h), at the end of study treatment infusion (< 5.5 h), and at 48 hours. Total MMP-9 and aMMP-9 increased very early after stroke onset in patients allocated vehicle after rtPA therapy. Lower increments of aMMP-9 were associated with better outcome at 3 months. UA treatment was associated with reduced levels of aMMP-9 at T1 (p < 0.02) in multivariate models adjusted for age, NIHSS score, and baseline aMMP-9 levels. The decline of aMMP-9 attained after UA administration supports further clinical assessment of UA therapy in patients with acute stroke.
机译：脑缺血后，氧化应激以及基质金属蛋白酶9（MMP-9）的表达和活性迅速增强。这些影响的程度与中风的结果有关。在人的中风中，氧化应激的程度与MMP-9表达增加密切相关。这项研究的目的是评估抗氧化剂分子尿酸（UA）的治疗是否能降低rtPA治疗的中风患者的MMP-9水平。这些患者是接受rtPA（<3 h）治疗的急性中风患者的双盲，随机，对照试验的随机对照研究的一部分，并随机接受UA（n = 16）或载体（n = 8）。在基线（<3小时），研究治疗输注结束（<5.5小时）和48小时时，测定血清中总基质金属蛋白酶（tMMP）-9和活性（aMMP-9）的水平。 rtPA治疗后分配媒介物的患者中风后不久，总MMP-9和aMMP-9升高。较低的aMMP-9增量与3个月时的较好结局相关。在针对年龄，NIHSS评分和基线aMMP-9水平进行调整的多变量模型中，UA治疗与T1时aMMP-9水平的降低有关（p <0.02）。 UA给药后aMMP-9的下降支持对急性中风患者进行UA治疗的进一步临床评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号